🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

GKB Ophthalmics Limited GKB NSEPHARMA

Healthcare · Medical Instruments & Supplies · India
https://gkb.net
Company Profile ↓
₹58.61
-33.70% 1Y
Mkt Cap₹29.54 Cr
P/E9.10
P/B0.65
52W High₹88.40
52W Low₹58.61
Book Value₹104.82
EPS (TTM)₹6.44

Company Overview

GKB Ophthalmics Limited engages in the manufacture and sale of unfinished ophthalmic lenses in India and internationally. It offers semifinished organic lenses, such as single vision, bifocal, and progressive. The company was incorporated in 1981 and is based in Mapusa, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 276.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 25.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 9.1, below the sector median of 35.9.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.21.

Recent Developments

  • Mar 2026 Revenue of ₹149.06 Cr (+36.8% YoY); net profit ₹1.22 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +2.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 25.5%, profit CAGR 276.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:25.52%
1 Year:2.30%

Compounded Profit Growth

5 Years:275.97%
1 Year:-

Stock Price Performance

1 Year:-33.70%
6 Months:-
3 Months:-
1 Month:-15.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 0% of range
₹58.61 ₹88.40
Trend Signals
  • Price vs 50-DMABelow
  • RSI (14)36.32 · Neutral
Price Performance
1M-15.19%
1Y-33.70%
Valuation vs Sector

P/E of 9.10 is below the sector median of 35.90 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 25.5% over 5 years.
  • Profit CAGR of 276.0% over 5 years.

CONS

  • Trading 33.7% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
9.10
Industry PE
35.90
Forward P/E est.
4.55
PEG Ratio
-
Book Value
₹104.82
Price to Book
0.65
P/S
0.23
EV/EBITDA
4.17
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
25.52%
Profit 5Y
275.97%
Revenue (YoY)
2.30%
Earnings (YoY)
-

Profitability & Returns

ROCE
8.85%
ROE
2.31%
ROA
0.92%
Profit Margin
2.17%
Op Margin
5.77%
Gross Margin
28.14%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹6.44

Balance Sheet & Liquidity

Debt/Equity
0.21
Quick Ratio
0.75
Current Ratio
1.52
Debt
₹11.66 Cr
Total Assets
₹132.17 Cr
Current Assets
₹107.96 Cr
Working Capital
₹36.77 Cr

Ownership

Promoter Holding
78.05%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹29.54 Cr
Total Revenue (TTM)
₹149.80 Cr
EBITDA
₹10.51 Cr
Free Cash Flow
₹-4.83 Cr
Operating Cash Flow
₹-3.81 Cr
Shares Outstanding
₹50.41 L
Gross Margin
28.14%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GKB GKB Ophthalmics Limited NSEPHARMA 58.61 9.10 ₹29.54 Cr 0.00% 8.85% 2.31% 25.52% 275.97%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 31.02 Cr32.31 Cr30.17 Cr56.79 Cr29.79 Cr
Cost of Revenue 22.51 Cr21.89 Cr18.55 Cr45.35 Cr19.60 Cr
Gross Profit 8.51 Cr10.41 Cr11.62 Cr11.44 Cr10.19 Cr
Operating Expenses 12.16 Cr10.40 Cr9.39 Cr10.91 Cr7.88 Cr
Operating Income -3.65 Cr71,0002.23 Cr53.94 L2.31 Cr
EBITDA -2.50 Cr1.00 Cr3.39 Cr2.23 Cr2.39 Cr
Interest Expense 63.04 L76.63 L65.60 L73.45 L51.77 L
Pretax Income -3.93 Cr-56.34 L1.91 Cr67.72 L1.08 Cr
Tax Provision 19.43 L7.73 L7.19 L-3.00 L-4.26 L
Net Income -3.55 Cr-1.02 Cr1.60 Cr44.30 L19.34 L
Diluted EPS -----

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 75.38 Cr88.25 Cr108.99 Cr149.06 Cr
Cost of Revenue 51.29 Cr62.89 Cr76.56 Cr107.56 Cr
Gross Profit 24.09 Cr25.37 Cr32.43 Cr41.51 Cr
Operating Expenses 23.20 Cr27.68 Cr38.08 Cr36.11 Cr
Operating Income 89.03 L-2.31 Cr-5.65 Cr5.40 Cr
EBITDA 4.26 Cr1.51 Cr-2.07 Cr8.17 Cr
Interest Expense 1.30 Cr1.38 Cr1.57 Cr1.83 Cr
Pretax Income 13.94 L-2.78 Cr-6.73 Cr3.10 Cr
Tax Provision 2.31 L20.62 L35.30 L7.66 L
Net Income -16.74 L-2.81 Cr-7.04 Cr1.22 Cr
Diluted EPS ----

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -112.09 Cr114.50 Cr125.21 Cr132.17 Cr
Current Assets -83.53 Cr87.48 Cr99.39 Cr107.96 Cr
Cash & Equivalents -2.36 Cr3.23 Cr3.02 Cr2.67 Cr
Inventory -38.74 Cr40.02 Cr50.38 Cr54.63 Cr
Receivables -27.74 Cr28.40 Cr25.49 Cr44.87 Cr
Total Liabilities -44.79 Cr50.30 Cr68.78 Cr77.28 Cr
Current Liabilities -41.09 Cr46.23 Cr62.39 Cr71.19 Cr
Long Term Debt -1.17 Cr1.05 Cr3.08 Cr1.57 Cr
Total Debt -11.22 Cr11.49 Cr14.50 Cr11.66 Cr
Total Equity -62.69 Cr59.77 Cr52.04 Cr52.83 Cr
Shares Outstanding -50.41 L50.41 L50.41 L50.41 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --2.77 Cr4.22 Cr-3.43 Cr-3.81 Cr
Investing Cash Flow -1.43 Cr-1.71 Cr2.55 Cr9.00 Cr
Financing Cash Flow --2.19 Cr-1.64 Cr66.88 L-5.55 Cr
Capital Expenditure --1.21 Cr-2.08 Cr-2.15 Cr-1.03 Cr
Free Cash Flow --3.99 Cr2.14 Cr-5.58 Cr-4.83 Cr
Net Change in Cash --3.53 Cr86.83 L-21.12 L-35.43 L

Ratios (Annual)

Figures in %.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % 32.0%28.7%29.8%27.8%
Operating Margin % 1.2%-2.6%-5.2%3.6%
Net Margin % -0.2%-3.2%-6.5%0.8%
ROE % -0.3%-4.7%-13.5%2.3%
ROCE % 1.3%-3.4%-9.0%8.9%

Shareholding Pattern

Insiders
78.05%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GKB

Google News Fri, 16 Oct 2026

Gkb Ophthalmics | Stock Share Price Live - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE56Y0tBcHNaN3Y0c0Vpcm9lbDRxWG84STJxQ3VjOXJESjdFcU10ZGJLSFpYVVFmR290dFQ4bUdpS0FxNUVfc3gtbmJUc0RoNURld1Jfdk5TeENYRm9lazMzNzNaQ3BKTmJROVoxbkFLU0Zmdw?oc=5" target="_blank">Gkb Ophthalmi…

Google News hu, 27 Aug 2026

GKB Ophthalmics Ltd. Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOYXV3dVhnUHZYZ0tmc211ZVluc2J5cmhyN2NwOUJxRzJSVUpFTFNCREI0VEhvZlJzaXlrcEN4MDctWFlMd3lpS3FhVWJ1SERRdlhlb2tIM1dWaVEwTzFQdkxKOFFrM3VZVzJ5M3FDd0M3TEc3ZDd1UHpWMEFxdzRhMGZ1MEtiekpncHc?oc…

Google News ue, 22 Sep 2026

GKB Ophthalmics reappoints K.G. Gupta as CMD for three years - scanx.trade

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPRnpQR2VER1pjdkJleFZERzhheWYzMWJaekpKeFRVVmhDVmxnTWJsZmJLdUdXaFJHRkx3dTFqa1owSzdnWU9hRTc1aTFNY3hia1N0NUNfRnVocHFrN1VuNkJfTWw1X3BPbVlUX2RzUXF6ZlB3dHZaQ3p2SWs4MGJsbGpvb2NMREdfYjZZOW…

Google News ue, 05 May 2026

GKB millionaire plaintiff is investor Remo Stoffel - blue News

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOMlhUSUx5RkJvLTZGR2liOTFRb0JDMmttSXBoQVp0QkVhNV9rZC1tRzFSMTU1VS1JTGxHQVZfT3BVanAtQ1VXWDJGTWRXdGpJdzZEQXV5UFBMNkpWeHp4aWs2aU12TXhJS3dZZmtTNUs1aGhRWGZqRENPajdBSFg0ODd0Z0J5YWxydk5aMU…

Google News Fri, 27 Dec 2024

Latest rolling stock procurements: Via Rail, SNCF, GTLK, CAF, MAV, GKB, TMH - rollingstockworld.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQY2M2cDdFeHVhTGNoLTc0YzlMSEtlQy1GeGZLbUk3RDRyeHFjMHNGeTlobUlNc0FScnBDQnN3ZVFBelAxYTh3OTFkQWlQbzJSUnpmbFJ4YnlLTnFLYkpubzhLbkpidVY1b2NBUkdJQ0Rvd1B3RXYwd1lLaEk0OGdkNlQ1ZWxXU0FOUFhKcz…

Google News Fri, 23 Oct 2026

Wells says turnover has created lack of trust at GKB - KPCNews

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOYi1sUEZiREM3cGxfbGcxaklfeWxGZmtUcElRS1pTMU16U1lpeGg2NEtPNDhLRENSSnVDVk53TzJMVW9NX2ZNemRmeWhkMXhvOFlESnFiVl96MGFVWkYta0dSdTdVSFdQaTdaWUZNS255MUk0X1gtN3VNUjJ6cWZ2Q2Z1Z0dDRWhKYVE?oc…

GKB — Frequently Asked Questions

What is the current share price of GKB Ophthalmics Limited (GKB)?

As of 2026-10-24 04:55 IST, GKB Ophthalmics Limited (GKB) trades at ₹58.61 on NSE. Its 52-week range is ₹58.61 to ₹88.40.

What is the market capitalisation of GKB?

GKB Ophthalmics Limited (GKB) has a market capitalisation of ₹29.54 Cr on NSE.

What is the P/E ratio of GKB?

GKB trades at a trailing price-to-earnings (P/E) ratio of 9.10. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 0.65.

What is the return on equity (ROE) of GKB?

GKB has a return on equity (ROE) of 2.31%. Its return on capital employed (ROCE) is 8.85%.

Is GKB a good stock to buy?

This page provides a data-driven analysis of GKB Ophthalmics Limited (GKB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space